KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Other financing activities (2016 - 2025)

Historic Other financing activities for Cme (CME) over the last 17 years, with Q3 2025 value amounting to -$4.3 million.

  • Cme's Other financing activities rose 227.27% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.0 million, marking a year-over-year increase of 4972.07%. This contributed to the annual value of -$9.2 million for FY2024, which is 107.53% up from last year.
  • Per Cme's latest filing, its Other financing activities stood at -$4.3 million for Q3 2025, which was up 227.27% from -$100000.0 recorded in Q2 2025.
  • Cme's Other financing activities' 5-year high stood at $3.7 million during Q2 2023, with a 5-year trough of -$8.9 million in Q4 2023.
  • For the 5-year period, Cme's Other financing activities averaged around -$2.1 million, with its median value being -$2.2 million (2021).
  • The largest annual percentage gain for Cme's Other financing activities in the last 5 years was 133333.33% (2023), contrasted with its biggest fall of 99000.0% (2023).
  • Cme's Other financing activities (Quarter) stood at -$400000.0 in 2021, then surged by 350.0% to $1.0 million in 2022, then tumbled by 990.0% to -$8.9 million in 2023, then skyrocketed by 97.75% to -$200000.0 in 2024, then crashed by 2050.0% to -$4.3 million in 2025.
  • Its Other financing activities stands at -$4.3 million for Q3 2025, versus -$100000.0 for Q2 2025 and -$4.4 million for Q1 2025.